Addex Therapeutics (NASDAQ:ADXN – Get Free Report) and Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.
Volatility & Risk
Addex Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
Valuation & Earnings
This table compares Addex Therapeutics and Ocular Therapeutix”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Addex Therapeutics | $55,345.00 | 165.00 | $8.02 million | ($5.87) | -1.47 |
| Ocular Therapeutix | $55.78 million | 44.91 | -$193.51 million | ($1.44) | -8.17 |
Addex Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Addex Therapeutics and Ocular Therapeutix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Addex Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Ocular Therapeutix | 1 | 1 | 12 | 0 | 2.79 |
Ocular Therapeutix has a consensus price target of $22.33, suggesting a potential upside of 89.91%. Given Ocular Therapeutix’s stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Addex Therapeutics.
Insider & Institutional Ownership
16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Addex Therapeutics and Ocular Therapeutix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Addex Therapeutics | 3,584.49% | -68.40% | -60.68% |
| Ocular Therapeutix | -382.51% | -71.92% | -49.36% |
Summary
Ocular Therapeutix beats Addex Therapeutics on 8 of the 14 factors compared between the two stocks.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
